Table 2.
Crude odds ratios (OR) for a successful outcome at one year predicted by characteristics at baseline, 4 months, and 1 year
| PGI-I | ICIQ-UI SF | Sufficient treatment | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Predictor | Success (n = 55) | Failure (n = 113) | OR (95 % CI) | Success (n = 95) | Failure (n = 71) | OR (95 % CI) | Success (n = 93) | Failure (n = 69) | OR (95 % CI) |
| Baseline characteristics | |||||||||
| Age (years) | 53.45 ± 9.50* | 48.73 ± 10.67* | 1.05 (1.02–1.09)* | 50.98 ± 10.12** | 49.63 ± 10.09** | 1.01(0.98–1.05)** | 53.68 ± 10.06* | 46.04 ± 8.61* | 1.09(1.05–1.13)* |
| Motivation | |||||||||
| 1–8 | 12 (26.1)** | 34 (73.9)** | 1.00** | 15 (34.1)* | 29 (65.9)* | 1.00*** | 19 (45.2)** | 23 (54.8)** | 1.00** |
| 9 | 9 (28.1)** | 23 (71.9)** | 1.11 (0.40–3.05)** | 21 (65.6)* | 11 (34.4)* | 3.69 (1.41–9.64)* | 18 (58.1)** | 13 (41.9)** | 1.68 (0.66–4.28)** |
| 10 | 34 (38.2)*** | 55 (61.8)*** | 1.75 (0.80–3.84)*** | 59 (66.3)* | 30 (33.7)* | 3.80 (1.77–8.15)* | 55 (62.5)** | 33 (37.5)** | 2.02 (0.96–4.25)** |
| Self-rated ability to do PFMT | |||||||||
| 1–9 | 25 (28.7)*** | 62 (71.3)*** | 1.00*** | 39 (45.9)* | 46 (54.1)* | 1.00* | 40 (48.8)* | 42 (51.2)* | 1.00*** |
| 10 | 30 (37.5)*** | 50 (62.5)*** | 1.49 (0.78–2.85)*** | 56 (70.0)* | 24 (30.0)* | 2.75 (1.45–5.22)* | 52 (65.8)* | 27 (34.2)* | 2.02 (1.07–3.82)* |
| Vaginal delivery >4,000 g | |||||||||
| No | 36 (34.6)** | 68 (65.4)** | 1.00** | 64 (61.5)*** | 40 (38.5)*** | 1.00*** | 53 (52.5)*** | 48 (47.5)*** | 1.00*** |
| Yes | 13 (26.5)** | 36 (73.5)** | 0.68 (0.32–1.45)** | 22 (46.8)*** | 25 (53.2)*** | 0.55 (0.27–1.10)*** | 29 (63.0)*** | 17 (37.0)*** | 1.55 (0.76–3.16)*** |
| Menopause | |||||||||
| No | 26 (27.7)*** | 68 (72.3)*** | 1.00*** | 49 (53.8)** | 42 (46.2)** | 1.00** | 39 (43.8)* | 50 (56.2)* | 1.00* |
| Yes | 27 (39.1)*** | 42 (60.9)*** | 1.68 (0.87–3.26)*** | 42 (60.0)** | 28 (40.0)** | 1.29 (0.68–2.42)** | 51 (75.0)* | 17 (25.0)* | 3.85 (1.93–7.67)* |
| Local estrogen | |||||||||
| No | 43 (29.9)* | 101 (70.1)* | 1.00* | 79 (56.0)** | 62 (44.0)** | 1.00** | 74 (53.6)* | 64 (46.4)* | 1.00* |
| Yes | 11 (52.4)* | 10 (47.6)* | 2.58 (1.02–6.53)* | 15 (68.2)** | 7 (31.8)** | 1.68 (0.65–4.38)** | 17 (81.0)* | 4 (19.9)* | 3.68 (1.18–11.49)* |
| Moderate physical activity | |||||||||
| < 3 h/week | 23 (40.4)*** | 34 (59.6)*** | 1.00*** | 36 (63.2)* | 21 (36.8)* | 1.00* | 33 (57.9)** | 24 (42.1)** | 1.00** |
| 3–5 h/week | 15 (27.8)*** | 39 (72.2)*** | 0.57 (0.26–1.26)*** | 23 (42.6)* | 31 (57.4)* | 0.43 (0.20–0.93)* | 26 (51.0)** | 25 (49.0)** | 0.76 (0.35–1.62)** |
| >5 h/week | 17 (29.8)*** | 40 (70.2)*** | 0.63 (0.29–1.37)*** | 36 (65.5)** | 19 (34.5)** | 1.11 (0.51–2.40)** | 34 (63.0)** | 20 (37.0)** | 1.24 (0.58–2.65)** |
| Tea, cups/day | |||||||||
| None | 18 (34.0)** | 35 (66.0)** | 1.00** | 33 (63.5)** | 19 (36.5)** | 1.00** | 29 (56.9)*** | 22 (43.1)*** | 1.00*** |
| 1–2 | 24 (28.9)** | 59 (71.1)** | 0.79 (0.38–1.66)** | 44 (53.0)*** | 39 (47.0)*** | 0.65 (0.32–1.32)*** | 43 (51.8)** | 40 (48.2)** | 0.82 (0.40–1.65)** |
| ≥ 3 | 13 (40.6)** | 19 (59.4)** | 1.33 (0.54–3.29)** | 18 (58.1)** | 13 (41.9)** | 0.80 (0.32–1.98)** | 21 (75.0)*** | 7 (25.0)*** | 2.28 (0.82–6.31)*** |
| ICIQ-UI SF | 10.18 ± 3.37** | 10.11 ± 3.13** | 1.01 (0.91–1.11)** | 11.51 ± 2.62* | 8.35 ± 2.62* | 1.49 (1.30–1.71)* | 9.80 ± 3.45*** | 10.54 ± 2.88*** | 0.93 (0.84–1.03)*** |
| ICIQ-LUTSqol | 33.44 ± 8.40** | 32.30 ± 5.85** | 1.03 (0.98–1.07)** | 34.49 ± 7.18* | 30.48 ± 5.55* | 1.11 (1.05–1.18)* | 32.73 ± 7.63** | 32.83 ± 5.79** | 0.10 (0.95–1.04)** |
| 4-month follow-up | |||||||||
| PGI-I | |||||||||
| Little better/much worse | 21 (19.6)* | 86 (80.4)* | 1.00* | 53 (49.5)* | 54 (50.5)* | 1.00* | 46 (44.2)* | 58 (55.8)* | 1.00* |
| Much better/very much better | 33 (55.0)* | 27 (45.0)* | 5.00 (2.49–10.05)* | 41 (70.7)* | 17 (29.3)* | 2.46 (1.24–4.85)* | 46 (80.0)* | 11 (19.3)* | 5.27 (2.46–11.31)* |
| MID ICIQ-UI SF | |||||||||
| <3 | 18 (26.5)*** | 50 (73.5)*** | 1.00*** | 21 (31.3)* | 46 (68.7)* | 1.00* | 32 (48.5)*** | 34 (51.5)*** | 1.00*** |
| ≥3 | 37 (37.4)*** | 62 (62.6)*** | 1.66 (0.84–3.26)*** | 73 (74.5)* | 25 (25.5)* | 6.40 (3.22–12.72)* | 60 (63.2)*** | 35 (36.8)*** | 1.82 (0.96–3.45)*** |
| MID ICIQ-LUTSqol | |||||||||
| < 4 | 17 (23.3)* | 56 (76.7)* | 1.00* | 30 (41.1)* | 43 (58.9)* | 1.00* | 31 (43.7)* | 40 (56.3)* | 1.00* |
| ≥ 4 | 37 (39.4)* | 57 (60.6)* | 2.14 (1.08–4.23)* | 65 (69.9)* | 28 (30.1)* | 3.33 (1.75–6.33)* | 62 (68.1)* | 29 (31.9)* | 2.76 (1.45–5.25)* |
| Sufficient treatment | |||||||||
| No | 13 (21.7)* | 47 (78.3)* | 1.00* | 30 (50.8)*** | 29 (49.2)*** | 1.00*** | 16 (27.1)* | 43 (72.9)* | 1.00* |
| Yes | 42 (40.0)* | 63 (60.0)* | 2.41 (1.16–4.99)* | 63 (60.6)*** | 41 (39.4)*** | 1.49 (0.78–2.82)*** | 77 (76.2)* | 24 (23.8)* | 8.62 (4.14–17.97)* |
| 1-year follow-up | |||||||||
| PFMT last 3 months | |||||||||
| Less than one time/week | 30 (26.5)* | 83 (73.5)* | 1.00* | 62 (54.9)** | 51 (45.1)** | 1.00** | 53 (49.1)* | 55 (50.9)* | 1.00* |
| Regularly, at least one time/week | 24 (45.3)* | 29 (54.7)* | 2.29 (1.16–4.53)* | 33 (63.5)** | 19 (36.5)** | 1.43 (0.73–2.81)** | 40 (75.5)* | 13 (24.5)* | 3.19 (1.54–6.63)* |
Values are presented as means (± standard deviation) or n (%)
ORs are the result of univariate logistic regression and are presented with a 95 % confidence interval (CI)
PGI-I Patient Global Impression of Improvement, PFMT pelvic floor muscle training
*p <0.05
**p >0.25
***p <0.25